Skin changes as a result of targeted therapies in oncology patients. Cutaneous side effects of targeted therapies in oncology patients

被引：0

作者：

Kaehler, K. C. ^{[1
]}

Hauschild, A. ^{[1
]}

机构：

[1] Univ Klinikum Schleswig Holstein, Klin Dermatol Venerol & Allergol, D-24105 Kiel, Germany

来源：

HAUTARZT | 2009年 / 60卷 / 05期

关键词：

Targeted therapies; Cutaneous side effects; Oncology; Interdisciplinary collaboration; Skin changes; IMATINIB; CANCER; SORAFENIB; ANTIGEN-4; BLOCKADE; ERUPTION;

D O I：

10.1007/s00105-009-1754-9

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The growing number of patients treated with modern targeted therapies that cause specific cutaneous side effects is drawing attention to the optimal management of these side effects. Experience to date has shown that good management allows the majority of patients to receive the treatment as planned. As a result of the link between dermatological side effects and the success of treatment than can be assumed to exist for many substances, interdisciplinary collaboration between dermatologists and professionals from other disciplines working in the field of oncology is becoming increasingly important.

引用

页码：433 / 439

页数：7

共 22 条

[1] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 [J].

Beck, Kimberly E. ;

Blansfield, Joseph A. ;

Tran, Khoi Q. ;

Feldman, Andrew L. ;

Hughes, Marybeth S. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Topalian, Suzanne L. ;

Sherry, Richard M. ;

Kleiner, David ;

Quezado, Martha ;

Lowy, Israel ;

Yellin, Michael ;

Rosenberg, Steven A. ;

Yang, James C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) :2283-2289

[2] Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib [J].

Breccia, M ;

Carmosino, I ;

Russo, E ;

Morano, SG ;

Latagliata, R ;

Alimena, G .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 74 (02) :121-123

[3]

BULANHAGUI CA, 2008, J CLIN ONCOL S, V26

[4] Drug therapy: EGFR antagonists in cancer treatment [J].

Ciardiello, Fortunato ;

Tortora, Giampaolo .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174

[5]

DIRSCHKA T, THERAPIE MANAGEMENT

[6] Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade [J].

Downey, Stephanie G. ;

Klapper, Jacob A. ;

Smith, Franz O. ;

Yang, James C. ;

Sherry, Richard M. ;

Royal, Richard E. ;

Kammula, Udai S. ;

Hughes, Marybeth S. ;

Allen, Tamika E. ;

Levy, Catherine L. ;

Yellin, Michael ;

Nich, Geoffrey ;

White, Donald E. ;

Steinberg, Seth M. ;

Rosenberg, Steven A. .

CLINICAL CANCER RESEARCH, 2007, 13 (22) :6681-6688

[7] Pimecrolimus: A novel treatment for cetuximab-induced papulopustular eruption [J].

Eiling, Elisabeth ;

Brandt, Michael ;

Schwarz, Thomas ;

Hauschild, Axel .

ARCHIVES OF DERMATOLOGY, 2008, 144 (09) :1236-1238

[8] Sunitinib and Periodic Hair Depigmentation Due to Temporary c-KIT Inhibition [J].

Hartmann, Joerg Thomas ;

Kanz, Lothar .

ARCHIVES OF DERMATOLOGY, 2008, 144 (11) :1525-1526

[9]

HAUSCHILD A, 2007, NEXAVAR BEIM NIERENZ

[10] Platelet-derived growth factor β receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling [J].

Heuchel, R ;

Berg, A ;

Tallquist, M ;

Åhlén, K ;

Reed, RK ;

Rubin, K ;

Claesson-Welsh, L ;

Heldin, CH ;

Soriano, P .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (20) :11410-11415

← 1 2 3 →